# NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
Canonical URL: https://biopharmsignal.com/news/NGM/ngm-bio-and-kdt-ventures-enter-into-worldwide-license-agreement-for-ngm313-a-phase-2-ready-fgfr1c-klotho-agonist-drug-candidate
Ticker: NGM
Company: NGM Biopharmaceuticals
Source: NGM Biopharmaceuticals
Published: 2024-12-19 12:01 EST
Original Source URL: https://ir.ngmbio.com
## Summary

KdT has formed a new company to develop NGM313 in a rare disease indication NGM Bio will receive up to $608 million in upfront and potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales and equity in the new company SOUTH SAN FRANCISCO, Calif.

## Article Body
KdT has formed a new company to develop NGM313 in a rare disease indication NGM Bio will receive up to $608 million in upfront and potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales and equity in the new company SOUTH SAN FRANCISCO, Calif.
## Recent Company News
- 2025-02-24 08:00 EST — [NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients](https://biopharmsignal.com/news/NGM/ngm-bio-announces-first-participant-dosed-in-emerald-phase-2-clinical-study-of-ngm120-for-the-treatment-of-hyperemesis-gravidarum-hg-in-pregnant-patients) — Source: NGM Biopharmaceuticals
- 2025-02-04 12:00 EST — [NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/NGM/ngm-bio-announces-appointment-of-wendy-yeh-m-d-as-chief-medical-officer) — Source: NGM Biopharmaceuticals
- 2024-12-19 12:01 EST — [NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate](https://biopharmsignal.com/news/NGM/ngm-bio-and-kdt-ventures-enter-into-worldwide-license-agreement-for-ngm313-a-phase-2-ready-fgfr1c-klotho-agonist-drug-candidate) — Source: NGM Biopharmaceuticals
- 2024-07-17 11:01 EST — [NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum](https://biopharmsignal.com/news/NGM/ngm-bio-announces-122-million-series-a-financing-to-initiate-registrational-trial-in-primary-sclerosing-cholangitis-and-fund-phase-2-trial-in-hyperemesis-gravidarum) — Source: NGM Biopharmaceuticals
- 2024-04-05 13:20 EST — [NGM Bio Announces Closing of Tender Offer](https://biopharmsignal.com/news/NGM/ngm-bio-announces-closing-of-tender-offer) — Source: NGM Biopharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)